Insurers: Mass. health care reaching 'limits of affordability'
New payment models could help alleviate the industry's financial woes, particularly in the primary care landscape, they said.
The heads of Blue Cross Blue Shield of Massachusetts, Fallon Health and WellSense Health Plan offered their sobering perspectives on cost and access challenges in front of hundreds of health care providers gathered at the Massachusetts Health and Hospital Association's annual meeting at the Westin Seaport.
'The challenges, no matter where you sit in the health care ecosystem right now, are profound,' Sarah Iselin, CEO of Blue Cross Blue Shield of Massachusetts, said during a panel discussion.
Iselin invoked nearly double-digit health care cost trends, which she attributed to steeper medications prices like GLP-1 weight-loss drugs and 'higher utilization increases across the board.' Iselin said those trends are driving losses among health insurers. Blue Cross had a 'pretty rough' last year, and that trend is expected through 2025, she said.
'It is going to have consequences that I think should concern all of the local payers because the faster health care costs grow, the more tempting it is for employers to go self-insured,' said Iselin, who warned that would 'invite more of the national payers into the market.'
Echoing Iselin's assessment, Fallon Health CEO Manny Lopes said both providers and payers are at a 'crisis point.' Meanwhile, WellSense Health Plan President Heather Thiltgen said Massachusetts is 'really starting to reach the limits of affordability, for our consumers, our employers and our taxpayers.'
Panelists also discussed initiatives their organizations are pursuing to manage health care costs and bolster access, with an eye toward pinpointing potential statewide strategies.
Assistant Secretary for MassHealth Mike Levine said state officials over the last two years 'significantly increased' investment in primary care by embracing a capitated payment model rather than a fee-for-service structure. That move creates a more predictable monthly revenue stream for primary care practices, Levine said.
'I don't think there are enough practices in Massachusetts with a high enough Medicaid payer mix for that to be the thing alone that will transform care and experience for providers and members,' Levine said. 'But we are eager to partner with providers and other payers to build a model of capitation in the primary care setting that will hopefully unlock some of the access that has been so hard to find.'
Gov. Maura Healey and Senate President Karen Spilka have pegged primary care as a priority for the new legislative session. A primary care task force, established through the new hospital oversight law, will produce recommendations to improve care access, delivery and financial sustainability.
Healey, during remarks earlier Thursday at the MHA meeting, said her fiscal 2026 budget proposal looks to boost MassHealth investment in primary care to '10% of its total spend moving forward.'
'We know that without that proper investment, we can't support our primary care workforce, we can't give patients better access to the care they deserve,' the governor said. 'And we think there's an opportunity for all of us together to look at how we can prioritize primary care.'
Lopes highlighted another capitated program at Fallon Health, which he said serves the frailest elderly members who are considered eligible for nursing homes but receive comprehensive at-home care.
'The goal is to try to keep those individuals out of institutions, living in the community and living healthy in the community, and bring all the support services for them and their families,' Lopes said. 'When I look at that model, it really is a model that we can apply to other frail populations or severely ill populations, where we really create an environment of capitated payment — create an environment where someone can come in and get the care that they need.'
Thiltgen said WellSense, which serves a large share of people with Medicaid and highly-subsidized ConnectorCare coverage, said members have 'considerable access problems' for behavioral and primary care. She said the health plan is exploring how to better integrate care, including for individuals with substance use disorder.
'We are experimenting with putting nurse practitioners in providers' offices so that we can help providers more efficiently understand who needs the care, and provide that bridge and help improve overall quality,' Thiltgen said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
30 minutes ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade
Yahoo
an hour ago
- Yahoo
Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?
Diabetes patients in the US will now be able to purchase Ozempic for half its usual cost. Novo Nordisk, a Danish pharmaceutical company, said on Monday that it would be providing the drug through its direct pharmacy service for $499 (£369) per month, instead of just under $1,000 per month. The drug giant said it had made a deal with healthcare firm GoodRx to make Wegovy, its obesity drug, available at this price in over 70,000 pharmacies nationwide. It comes after Novo Nordisk saw sales plummet last month, after competition ramped up in the US. The company said the profit warning came as a result of 'persistent use' of compounded – or copycat – versions of its drugs, as well as 'slower-than-expected market expansion and competition'. It has faced serious competition from Mounjaro, Eli Lilly's rival weight loss jab, as well as what it described as 'unsafe and unlawful mass compounding' in the market as weight loss and diabetes drugs have soared in popularity. Ozempic and Wegovy both contain glucagon-like peptide-1 (GLP-1). It works by stimulating insulin secretion, which is why it helps patients with type 2 diabetes, but it also signals fullness to the brain. Wegovy only triggers the GLP-1 receptor in the brian but Mounjaro works on both GLP-1 and GIP receptors, which can lead to more weight loss. In March, Novo Nordisk reduced the cost of Wegovy for cash-paying patients, but now people without health insurance will be able to purchase it for this price. Trump's critique The move comes just weeks after President Donald Trump criticised GLP-1 agonists for being more expensive in the US than in other countries, adding that he would 'slash the cost of prescription drugs' by 80 per cent. Last month, Trump wrote to pharmaceutical leaders demanding that they 'negotiate harder with foreign freeloading nations'. He said: 'increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers'. He's since upped that number, saying he would cut drug prices up to '1,500 percent,' which is mathematically impossible without entering negative numbers. He also said that European nations were 'unfairly shifting the cost burden onto American patients' by using their healthcare services to put pressure on US pharma companies to accept lower prices. Novo Nordisk said that the price cut was unrelated to discussions with the US government. Pfizer CEO Albert Boula has said he and other pharma companies are in talks about making their drugs available at a lower cost. Will it impact the UK cost? In the UK, patients can buy a four-week supply of Ozempic for between £119 and £190 from online pharmacies. Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump. In a statement, it said it would continue to focus 'on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most'. However, last week, weight-loss drugmaker Eli Lilly said it would increase UK prices by as much as 170pc due to concerns about unfair pricing. The company said obesity drug Mounjaro would rise in price from Sept 1 in order to address 'pricing inconsistencies compared to other developed countries, including in Europe'. The company's weight-loss jab will cost between £133 and £330 per injection (depending on dosage) in the UK. CheqUp, a weight-loss jab provider, reported that sales of Wegovy increased more than 500pc, following the Eli Lilly announcement.
Yahoo
an hour ago
- Yahoo
knownwell Strengthens Regional Footprint, Opens Second Clinic in the Greater Boston Area
The Company Unveils its Seventh New Weight-Inclusive Care Location in the Last Year, Increasing Patient Population by Nearly 400% BOSTON, August 19, 2025--(BUSINESS WIRE)--knownwell, an in-person and virtual weight-inclusive primary care and metabolic health company that opened its flagship clinic in Needham, Massachusetts in 2023, announces the deepening of its physical presence in the greater Boston area. As the company continues to increase access to weight-inclusive care across the country, the opening of a new clinic will provide additional opportunities for in-person engagement with locally based patients near Woburn, Massachusetts. The news comes on the heels of knownwell opening seven new clinics in the last year, including one in Dallas and six in Chicago, to provide in-person care in the Midwest and South Central regions. It also follows the company's launch of virtual metabolic care to patients in all 50 U.S. states. Today, more than half of adults in Massachusetts are affected by overweight or obesity. In Woburn alone, 1 in 4 adults has obesity. With few options for comprehensive metabolic care in the area, the addition of a new local clinic comes at a pivotal time to support those in need. "Boston has always held a special place in our story – it is where our mission began, and where we proved that weight-inclusive care can change lives," said Brooke Boyarsky Pratt, CEO and Co-Founder of knownwell. "This expansion isn't just about growth; it's about meeting an urgent need in a community that has inspired us from day one. Expanding our footprint here reflects both the significant need and our dedication to delivering accessible, whole-person care to help more people in Massachusetts achieve lasting health." The Woburn clinic arrives amid the demand for GLP-1 medications surging and the cost of treatment continuing to rise, creating new barriers for patients seeking effective, long-term solutions for obesity and overweight. By growing its presence in Massachusetts, the company aims to bridge this gap, delivering treatment that combines clinical, nutritional, and behavioral support to ensure patients receive the full spectrum of care they need to improve their health and quality of life. "When I moved to Massachusetts decades ago, it was to be part of a movement to treat obesity like the chronic disease it is – with science, compassion, and comprehensive care. This expansion in greater Boston is the next chapter in that mission, with knownwell leading the charge," said Chief Medical Officer and Co-Founder of knownwell, Dr. Angela Fitch. "By increasing access to integrated treatment, we're not just helping individuals improve their health but taking meaningful steps toward reducing obesity rates across the country." With the new opening, knownwell will additionally onboard Dr. Giovanna Leddy, President of the New England Obesity Society, as the new Market Medical Director, overseeing both the Woburn and Needham practices. Dr. Leddy serves as the Associate Director of the Social Justice Pathway within the Internal Medicine Residency Program at Beth Israel Deaconess Medical Center and currently practices Obesity Medicine at Atrius Health. She is also a Clinical Instructor in Medicine at Harvard Medical School. knownwell is on a mission to make weight-inclusive healthcare more accessible. It offers full-coverage care, including metabolic health services, comprehensive primary care, nutrition counseling, and behavioral health services online and in person, and accepts insurance. To learn more about knownwell, visit ABOUT KNOWNWELL: knownwell is built for the millions of Americans who have been told that their weight is the problem, regardless of their unique health concerns. Stigmatizing patients does not promote wellness, and in fact, leads to worse health outcomes. knownwell practices evidence-based medicine that supports a patient's unique goals, creating a healthcare home for patients with overweight and obesity. To learn more, visit View source version on Contacts Karalyn HooverSolCommsknownwell@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data